
|Slideshows|June 28, 2018
ADA 2018: CV Benefits of SGLT-2 Inhibitors
Author(s)Kenneth J. Bender, PharmD, MA
Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.
Advertisement
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves GSK's Depimokimab for Severe Asthma with Th2 Inflammation, First Ultra-Long Acting Biologic
2
Key Advances in Mental Health Research in 2025 for Primary Care
3
With Colonoscopy Capacity Limited, We Need More Momentum Behind Noninvasive Home-Based Tests, Says Mark Fendrick, MD
4
After ACIP Debate, CDC Modifies Longstanding Hepatitis B Birth Dose Recommendation
5


















































































































































































































































































